{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:49:27Z","timestamp":1790027367335,"version":"4.0.1"},"publisher-location":"Chichester, UK","reference-count":74,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd006650.pub3","type":"reference-entry","created":{"date-parts":[[2011,6,7]],"date-time":"2011-06-07T23:49:44Z","timestamp":1307490584000},"source":"Crossref","is-referenced-by-count":19,"title":["Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer"],"prefix":"10.1002","author":[{"given":"Elie A","family":"Akl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawman","family":"Labedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Terrenato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sperati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Muti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Sch\u00fcnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,6,15]]},"reference":[{"key":"10.1002\/14651858.CD006650.pub3-BIB1|cit1","series-title":"Supplement to Circulation","first-page":"Abstract 2875","article-title":"Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients","author":"Cesarone","year":"2003"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub3-BIB2|cit2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clinical & Applied Thrombosis\/Hemostasis"},{"issue":"12","key":"10.1002\/14651858.CD006650.pub3-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"American Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006650.pub3-BIB4|cit4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub3-BIB5|cit5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1067\/mva.2001.109336","article-title":"Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis","volume":"33","author":"Lopez-Beret","year":"2001","journal-title":"Journal of Vascular Surgery"},{"issue":"15","key":"10.1002\/14651858.CD006650.pub3-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD006650.pub3-BIB7|cit7","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.avsg.2009.08.006","article-title":"Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism","volume":"24","author":"Romera-Villegas","journal-title":"Iguaz Annals of Vascular Surgery"},{"issue":"18","key":"10.1002\/14651858.CD006650.pub3-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","article-title":"Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran","volume":"349","author":"Schulman","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006650.pub3-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub3-BIB10|cit10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1227\/00006123-199007000-00010","article-title":"The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors","volume":"27","author":"Altschuler","year":"1990","journal-title":"Neurosurgery"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub3-BIB11|cit11","first-page":"235","article-title":"Management of thrombosis in the cancer patient","volume":"1","author":"Andrea","year":"2003","journal-title":"Journal of Supportive Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub3-BIB12|cit12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2796.1998.00317.x-i1","article-title":"Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulation","volume":"244","author":"Astermark","year":"1998","journal-title":"Journal of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006650.pub3-BIB13|cit13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1055\/s-0037-1613395","article-title":"Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism","volume":"89","author":"Beckman","year":"2003","journal-title":"Thrombosis & Haemostasis"},{"issue":"10","key":"10.1002\/14651858.CD006650.pub3-BIB14|cit14","first-page":"3207","article-title":"Thrombin generation and activity are increased in patients with cancer receiving sodium warfarin as secondary prophylaxis against venous thrombosis","volume":"90","author":"Bona","year":"1997","journal-title":"Blood"},{"issue":"5936","key":"10.1002\/14651858.CD006650.pub3-BIB15|cit15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/bmj.4.5936.96","article-title":"Blood and neoplastic diseases. Thrombosis: treatment and prophylaxis","volume":"4","author":"Browse","year":"1974","journal-title":"British Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub3-BIB16|cit16","first-page":"3","article-title":"Comparative study of the clinical efficacy of two different coumarin dosages in the management of arm lymphedema after treatment for breast cancer","volume":"32","author":"Burgos","year":"1999","journal-title":"Lymphology"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub3-BIB17|cit17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0002-9378(16)32227-X","article-title":"Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy","volume":"147","author":"Clarke-Pearson","year":"1983","journal-title":"American Journal of Obstetrics & Gynecology"},{"issue":"11","key":"10.1002\/14651858.CD006650.pub3-BIB18|cit18","first-page":"843","article-title":"Heparin prevents recurrent VTE in cancer patients","volume":"52","author":"Clenney","year":"2003","journal-title":"Journal of Family Practice"},{"issue":"5","key":"10.1002\/14651858.CD006650.pub3-BIB19|cit19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s002689900081","article-title":"Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial","volume":"20","author":"Das","year":"1996","journal-title":"World Journal of Surgery"},{"issue":"6","key":"10.1002\/14651858.CD006650.pub3-BIB20|cit20","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ejvs.2004.02.029","article-title":"Long-term treatment of deep venous thrombosis with a low molecular weight heparin (Tinzaparin): a prospective randomized trial","volume":"29","author":"Daskalopoulos","year":"2005","journal-title":"European Journal of Vascular and Endovascular Surgery"},{"issue":"3","key":"10.1002\/14651858.CD006650.pub3-BIB21|cit21","first-page":"522","article-title":"Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran","volume":"94","author":"Eriksson","year":"2005","journal-title":"Thrombosis & Haemostasis"},{"key":"10.1002\/14651858.CD006650.pub3-BIB22|cit22","series-title":"2004 ASCO Annual Meeting Proceedings","article-title":"Multifactorial etiology of cancer associated venous thrombosis: results from profiling of cancer patients recruited in a study of the secondary prevention of thrombosis with low molecular weight heparin","author":"Farred","year":"2004"},{"issue":"16","key":"10.1002\/14651858.CD006650.pub3-BIB23|cit23","first-page":"765S","article-title":"Meta-analysis of the randomized comparisons between low-molecular weight heparin (LMWH) with oral anticoagulants (OA) for the long-term treatment of symptomatic venous thromboembolism (VTE): no difference in cancer-related mortality","volume":"23","author":"Ferretti","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD006650.pub3-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/annonc\/mdl092","article-title":"Does low-molecular-weight heparin influence cancer-related mortality?","volume":"17","author":"Ferretti","year":"2006","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD006650.pub3-BIB25|cit25","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.293.6.681","article-title":"Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis - A randomized trial","volume":"293","author":"Fiessinger","year":"2005","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD006650.pub3-BIB26|cit26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0741-5214(99)70139-4","article-title":"Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis","volume":"30","author":"Gonzalez-Fajardo","year":"1999","journal-title":"Journal of Vascular Surgery"},{"key":"10.1002\/14651858.CD006650.pub3-BIB27|cit27","first-page":"S4","article-title":"Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis","volume":"2","author":"Hull","year":"1996","journal-title":"Clinical and Applied Thrombosis-Hemostasis"},{"issue":"1 (Suppl 1)","key":"10.1002\/14651858.CD006650.pub3-BIB28|cit28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s003900070014","article-title":"A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis","volume":"37","author":"Hull","year":"2000","journal-title":"Intensivmedizin und Notfallmedizin"},{"issue":"2-3","key":"10.1002\/14651858.CD006650.pub3-BIB29|cit29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.disamonth.2005.03.011","article-title":"Long-term anticoagulation prophylaxis following acute thromboembolism","volume":"51","author":"Hyers","year":"2005","journal-title":"Disease-a-Month"},{"issue":"9","key":"10.1002\/14651858.CD006650.pub3-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1046\/j.1538-7836.2003.00364.x","article-title":"Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants","volume":"1","author":"Iorio","year":"2003","journal-title":"Journal of Thrombosis & Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD006650.pub3-BIB31|cit31","first-page":"468","article-title":"Warfarin dose requirements in cancer and non-cancer","volume":"25","author":"King","year":"2005","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1002\/14651858.CD006650.pub3-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1160\/TH05-01-0052","article-title":"Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients","volume":"93","author":"Kovacs","year":"2005","journal-title":"Thrombosis & Haemostasis"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub3-BIB33|cit33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1191\/1358863x05vm634oa","article-title":"Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism","volume":"10","author":"Kucher","year":"2005","journal-title":"Vascular Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006650.pub3-BIB34|cit34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1073274805012003S04","article-title":"Treatment of venous thromboembolism in cancer patients","volume":"12","author":"Lee","year":"2005","journal-title":"Cancer Control"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub3-BIB35|cit35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2217\/14750708.3.4.461","article-title":"Dalteparin sodium in the management of thromboembolic disorder","volume":"3","author":"Lee","year":"2006","journal-title":"Therapy"},{"issue":"2","key":"10.1002\/14651858.CD006650.pub3-BIB36|cit36","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1055\/s-0038-1649783","article-title":"Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis","volume":"74","author":"Levine","year":"1995","journal-title":"Thrombosis & Haemostasis"},{"issue":"7","key":"10.1002\/14651858.CD006650.pub3-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1046\/j.1538-7836.2003.00275.x","article-title":"From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer","volume":"1","author":"Levine","year":"2003","journal-title":"Journal of Thrombosis & Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub3-BIB38|cit38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-0037-1614412","article-title":"Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis","volume":"81","author":"Lopaciuk","year":"1999","journal-title":"Thrombosis & Haemostasis"},{"issue":"5","key":"10.1002\/14651858.CD006650.pub3-BIB39|cit39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1056\/NEJM199902043400503","article-title":"Lack of effect of coumarin in women with lymphedema after treatment for breast cancer","volume":"340","author":"Loprinzi","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"2-3","key":"10.1002\/14651858.CD006650.pub3-BIB40|cit40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0049-3848(03)00059-8","article-title":"An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial","volume":"109","author":"Massicotte","year":"2003","journal-title":"Thrombosis Research"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub3-BIB41|cit41","first-page":"34","article-title":"New oral anticoagulant and cancer drug believed to be firsts","volume":"144","author":"McCan","year":"2000","journal-title":"Drug Topics"},{"issue":"12","key":"10.1002\/14651858.CD006650.pub3-BIB42|cit42","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1001\/archinte.1987.00370120113020","article-title":"Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter?","volume":"147","author":"Olin","year":"1987","journal-title":"Archives of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006650.pub3-BIB43|cit43","first-page":"805","article-title":"A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy","volume":"84","author":"Palareti","year":"2000","journal-title":"Thrombosis & Haemostasis"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub3-BIB44|cit44","first-page":"322","article-title":"Therapy of deep vein thrombosis with low molecular weight heparin, compression and walking exercises","volume":"7","author":"Partsch","year":"2001","journal-title":"Anales de Cirugia Cardiaca y Cirugia Vascular"},{"issue":"20","key":"10.1002\/14651858.CD006650.pub3-BIB45|cit45","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1161\/01.CIR.103.20.2453","article-title":"Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis","volume":"103","author":"Pinede","year":"2001","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD006650.pub3-BIB46|cit46","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0038-1648837","article-title":"Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis","volume":"72","author":"Pini","year":"1994","journal-title":"Thrombosis & Haemostasis"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub3-BIB47|cit47","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1538-7836.2006.01795.x","article-title":"Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months","volume":"4","author":"Schulman","year":"2006","journal-title":"Journal of Thrombosis & Haemostasis"},{"key":"10.1002\/14651858.CD006650.pub3-BIB48|cit48","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1093\/ajhp\/62.22_Supplement_5.S7","article-title":"Considerations and challenges with existing treatments for thrombosis in cancer patients","volume":"62","author":"Schwartz","year":"2005","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"3","key":"10.1002\/14651858.CD006650.pub3-BIB49|cit49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/ebm.8.3.85","article-title":"In patients with cancer and venous thromboembolism (VTE), enoxaparin was as effective as warfarin for VTE prophylaxis and reduced fatal haemorrhage","volume":"8","author":"Scott","year":"2003","journal-title":"Evidence Based Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006650.pub3-BIB50|cit50","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0025-7125(16)31117-8","article-title":"Diagnosis and treatment of recurrent venous thromboembolism","volume":"68","author":"Shattil","year":"1984","journal-title":"Medical Clinics of North America"},{"issue":"9","key":"10.1002\/14651858.CD006650.pub3-BIB51|cit51","first-page":"1317","article-title":"Optimizing the duration of anticoagulation therapy for venous thrombosis","volume":"160","author":"Solymoss","year":"1999","journal-title":"Canadian Medical Association Journal"},{"issue":"11","key":"10.1002\/14651858.CD006650.pub3-BIB52|cit52","doi-asserted-by":"crossref","first-page":"102B","DOI":"10.1182\/blood.V104.11.4065.4065","article-title":"Treatment of deep vein thrombosis with enoxaparin in pediatric cancer patients receiving chemotherapy","volume":"104","author":"Stine","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD006650.pub3-BIB53|cit53","doi-asserted-by":"crossref","first-page":"903","DOI":"10.6004\/jnccn.2006.0075","article-title":"Long-term therapy of venous thromboembolism in cancer patients","volume":"4","author":"Streiff","year":"2006","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"3","key":"10.1002\/14651858.CD006650.pub3-BIB54|cit54","first-page":"134","article-title":"Treatment of deep vein thrombosis with low molecular weight heparins at home","volume":"20","author":"Suarez Alvarez","year":"2003","journal-title":"Anales de Medicina Interna"},{"issue":"8","key":"10.1002\/14651858.CD006650.pub3-BIB55|cit55","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1046\/j.1538-7836.2003.00293.x","article-title":"Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation","volume":"1","author":"Taliani","year":"2003","journal-title":"Journal of Thrombosis And Haemostasis"},{"key":"10.1002\/14651858.CD006650.pub3-BIB56|cit56","first-page":"215","article-title":"Antithrombophilic effect of low molecular weight heparins in patients with deep vein thrombosis","volume":"28","author":"Tedoldi","year":"1993","journal-title":"Clinical Trials and Meta-Analysis"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub3-BIB57|cit57","first-page":"559","article-title":"Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial","volume":"84","author":"Veiga","year":"2000","journal-title":"Thrombosis & Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD006650.pub3-BIB58|cit58","first-page":"296","article-title":"Treatment of deep vein thrombosis with oral anticoagulants ill patients with malignancy: prospective cohort study","volume":"43","author":"Vucic","year":"2002","journal-title":"Croatian Medical Journal"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006650.pub3-BIB59|cit59","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"10.1002\/14651858.CD006650.pub3-BIB60|cit60","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub3-BIB61|cit61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000081508","article-title":"Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months","volume":"33","author":"Conti","year":"2003","journal-title":"Pathophysiology of Haemostasis & Thrombosis"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub3-BIB62|cit62","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1055\/s-0038-1657514","article-title":"Prevention of post-operative deep leg vein thrombosis in patients with cancer","volume":"78","author":"Gallus","year":"1997","journal-title":"Thrombosis and Haemostasis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006650.pub3-BIB63|cit63","first-page":"383","article-title":"Clinical expertise in the era of evidence-based medicine and patient choice","volume":"83","author":"Haynes","year":"2002","journal-title":"Vox Sanguinis"},{"issue":"6","key":"10.1002\/14651858.CD006650.pub3-BIB64|cit64","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1001\/archinte.160.6.809","article-title":"Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study","volume":"160","author":"Heit","year":"2000","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD006650.pub3-BIB65|cit65","unstructured":"Higgins J Publication bias and funnel plots Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 2006 151 4"},{"issue":"1","key":"10.1002\/14651858.CD006650.pub3-BIB66|cit66","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1055\/s-0038-1646191","article-title":"Low molecular weight heparin","volume":"70","author":"Hirsh","year":"1993","journal-title":"Thrombosis & Haemostasis"},{"issue":"17","key":"10.1002\/14651858.CD006650.pub3-BIB67|cit67","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2000.18.17.3078","article-title":"Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis","volume":"18","author":"Hutten","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD006650.pub3-BIB68|cit68","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0002-9610(70)80023-X","article-title":"Deep vein thrombosis of the leg. Is there a \"high risk\" group?","volume":"120","author":"Kakkar","year":"1970","journal-title":"American Journal of Surgery"},{"issue":"5","key":"10.1002\/14651858.CD006650.pub3-BIB69|cit69","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00005792-199909000-00001","article-title":"Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using medicare claims data","volume":"78","author":"Levitan","year":"1999","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD006650.pub3-BIB70|cit70","first-page":"553","article-title":"When to believe a subgroup analysis","volume-title":"Users' guides to the medical literature: a manual for evidence-based clinical practice users' guides to the medical literature: a manual for evidence-based clinical practice","author":"Oxman","year":"2002"},{"key":"10.1002\/14651858.CD006650.pub3-BIB71|cit71","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD006650.pub3-BIB72|cit72","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"25","key":"10.1002\/14651858.CD006650.pub3-BIB73|cit73","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"Sorensen","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006650.pub3-BIB74|cit74","article-title":"Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism","author":"Heijden","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006650.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T00:00:00Z","timestamp":1404777600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD006650.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:02:18Z","timestamp":1628546538000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006650.pub3"}},"subtitle":[],"editor":[{"given":"Elie A","family":"Akl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,6,15]]},"references-count":74,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006650.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD006650.pub4","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2011,6,15]]}}}